ORENCIA (Abatacept) Supplemental Biologics License Application For Juvenile Idiopathic Arthritis Accepted By FDA For Filing And Review
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the supplemental biologics license application (sBLA) for ORENCIA (abatacept) for the treatment of pediatric patients with juvenile idiopathic arthritis (JIA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists. [click link for full article]
Osteoporosis Testing Good for Men, Too
Title: Osteoporosis Testing Good for Men, Too
Category: Health News
Created: 8/8/2007
Last Editorial Review: 8/8/2007
Health Tip: While Chewing Gum May Relieve Stress ...
Title: Health Tip: While Chewing Gum May Relieve Stress ...
Category: Health News
Created: 8/23/2007 2:00:00 AM
Last Editorial Review: 8/23/2007
